Objective:This study aims to evaluate the clinical efficacy of non-invasive positive pressure ventilation(NIPPV)in patients with severe bronchial asthma combined with respiratory failure.Methods:90 patients with sever...Objective:This study aims to evaluate the clinical efficacy of non-invasive positive pressure ventilation(NIPPV)in patients with severe bronchial asthma combined with respiratory failure.Methods:90 patients with severe bronchial asthma combined with respiratory failure between September 2022 and December 2023 were selected for the study and randomly divided into the experimental group(NIPPV-assisted treatment)and the control group.The differences between the two groups were compared in terms of total effective rate of treatment,days of clinical symptom disappearance,days of hospitalization,lung function indexes,incidence of adverse reactions,and quality of life.Results:Patients in the experimental group had a significantly higher total effective rate of treatment(97.78%)than the control group(75.56%).In terms of pulmonary function indexes,patients in the experimental group showed significant improvement after treatment,especially the increase in forced expiratory volume and forced vital capacity,while these improvements were not as obvious in the control group.In addition,the incidence of adverse reactions was significantly lower in the experimental group than in the control group,suggesting that the application of NIPPV is relatively safe.Quality of life assessment also showed that patients in the experimental group had significantly better quality of life than the control group after treatment.Conclusion:This study demonstrated the effectiveness of NIPPV as an adjunctive treatment for severe bronchial asthma combined with respiratory failure.NIPPV can improve lung function,reduce the incidence of adverse effects,increase the overall effectiveness of the treatment,and contribute to the improvement of patients'quality of life.Therefore,NIPPV should be regarded as an effective and safe treatment in clinical management,especially in patients with severe bronchial asthma combined with respiratory failure,where its application has potential clinical significance.展开更多
Objective: This study was aimed to compare the efficacy among chronic asthma patients who received 1 course treatment, 2 courses treatment and 3 courses treatment of Tianjiu Therapy in Sanfu Days. Methods: This study ...Objective: This study was aimed to compare the efficacy among chronic asthma patients who received 1 course treatment, 2 courses treatment and 3 courses treatment of Tianjiu Therapy in Sanfu Days. Methods: This study was comparing efficiency with 3 courses (baseline, the 1st course, the 2nd course, the 3rd course) of Tianjiu Therapy for asthma in 91 chronic asthma patients. For each course, patients received 3 times Tianjiu Therapy treatments, pretreatment assessment and posttrestment assessment. Results: 91 asthma participants completed at least 3 courses of Tianjiu Therapy in Sanfu Days. 1) Days for asthma attacked during the last 12 months;the frequency for asthma attacked during the last 12 months;incidence of admitting to clinic (Integrated Chinese Medicine & Western Medicine Clinic) when asthma attack during the last 12 months;times of admitting to clinic;times of solving by persistent medicine;times of solving by own medicine when asthma attack during the last 12 months;and symptoms associated with Chinese medicine of waking by asthma symptoms, lack of strength, lassitude, rapid or difficult breathing were improved at the 1st course, the 2nd course and the 3rd course compared with baseline (All P < 0.05);2) The incidence of admitting to In-patient Hospital and solving by persistent prescription when asthma attacked;the frequency of Chinese Herbal Medicine used during Tianjiu Therapy;the status of asthma under controlled and no improved by self-evaluation were similarly improved at the 2nd course and the 3rd course (All P 3) Incidence of admitting to A & E for asthma attacked during the last 12 months, and other treatments except Western Medicine, Chinese Herbal Medicine, and Acupuncture & Moxibution during the last 12 months were improvement at the 3rd course (All P 4) Symptoms associated with Chinese medicine of spontaneous sweating and reduction of exercise were improved at the 1st course (P < 0.05);5) Symptom of diarrhea after intake of oil food was became a little bad at the 2nd course and the 3rd course (P < 0.05);6) The frequency of bronchodilator used when asthma attack was reduced in the 1st course and the 2nd course (All P < 0.05);7) Lung function of FEV1 and FEV1/FVC(×100) were a little improvement, but have no significant statistical difference (P > 0.05);8) The total score of ACT at the 1st course, the 2nd course, and the 3rd course did not improved significantly (All P > 0.05). Conclusion: After Tianjiu Therapy in Sanfu Days participants have achieved good efficiency, and as the course get longer, the efficiency of more symptoms associated with chronic asthma were improved. Suggest patients with chronic asthma continuous receive Tianjiu Therapy in Sanfu Days which will be a feasible treatment.展开更多
In the present paper, the therapeutic effect of acupoint application of Chinese Materia Medica in the treatment of allergic asthma was observed. The results revealed that topical application of drug paste [mixture of ...In the present paper, the therapeutic effect of acupoint application of Chinese Materia Medica in the treatment of allergic asthma was observed. The results revealed that topical application of drug paste [mixture of powder of Mahuang (Herba Ephedrae), Xixin (Herba Asari), Baijiezi (Semen Sinapis Albae), etc.] at the acupuncture points could improve symptoms and signs of allergic asthma patients, with the total effective rate being 69.57% (16/23) for the short term effect, and 52.17%(12/23) for the long term effect. In medication (Aminophylline) group, of the 25 cases of allergic asthma, 16 (64.0%) were effective after 4 weeks of treatment, while 6 (24.0%) were still effective that was shown by 6 months’ follow up. The therapeutic effect of acupoint application group was significantly better than that of medication group in the long term effect. Results also showed that no obvious interrelation between the short term therapeutic effect and the duration or the severity of the disease. Results also display that acupoint application therapy is an effective, safe and handy method with fewer side effects for asthma.展开更多
【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMe...【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMed、Web of Science等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验,应用Stata14对数据进行网状Meta分析。【结果】最终纳入28项研究,包括7种中成药,分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示,在提高总有效率方面,优选概率排名曲线(surface under the cumulative ranking curve,SUCRA)的概率排序居前3位的依次为痰热清注射液联合吸入疗法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法;改善肺功能指标呼气峰值流速(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume at one second,FEV1)、FEV1与用力肺活量(forced vital capacity,FVC)的比值(FEV1/FVC)最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法;对不良反应发生率的SUCRA概率排序的分析结果显示,小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施,珠贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘的有效率及改善肺功能指标,且安全性较好。展开更多
文摘Objective:This study aims to evaluate the clinical efficacy of non-invasive positive pressure ventilation(NIPPV)in patients with severe bronchial asthma combined with respiratory failure.Methods:90 patients with severe bronchial asthma combined with respiratory failure between September 2022 and December 2023 were selected for the study and randomly divided into the experimental group(NIPPV-assisted treatment)and the control group.The differences between the two groups were compared in terms of total effective rate of treatment,days of clinical symptom disappearance,days of hospitalization,lung function indexes,incidence of adverse reactions,and quality of life.Results:Patients in the experimental group had a significantly higher total effective rate of treatment(97.78%)than the control group(75.56%).In terms of pulmonary function indexes,patients in the experimental group showed significant improvement after treatment,especially the increase in forced expiratory volume and forced vital capacity,while these improvements were not as obvious in the control group.In addition,the incidence of adverse reactions was significantly lower in the experimental group than in the control group,suggesting that the application of NIPPV is relatively safe.Quality of life assessment also showed that patients in the experimental group had significantly better quality of life than the control group after treatment.Conclusion:This study demonstrated the effectiveness of NIPPV as an adjunctive treatment for severe bronchial asthma combined with respiratory failure.NIPPV can improve lung function,reduce the incidence of adverse effects,increase the overall effectiveness of the treatment,and contribute to the improvement of patients'quality of life.Therefore,NIPPV should be regarded as an effective and safe treatment in clinical management,especially in patients with severe bronchial asthma combined with respiratory failure,where its application has potential clinical significance.
文摘Objective: This study was aimed to compare the efficacy among chronic asthma patients who received 1 course treatment, 2 courses treatment and 3 courses treatment of Tianjiu Therapy in Sanfu Days. Methods: This study was comparing efficiency with 3 courses (baseline, the 1st course, the 2nd course, the 3rd course) of Tianjiu Therapy for asthma in 91 chronic asthma patients. For each course, patients received 3 times Tianjiu Therapy treatments, pretreatment assessment and posttrestment assessment. Results: 91 asthma participants completed at least 3 courses of Tianjiu Therapy in Sanfu Days. 1) Days for asthma attacked during the last 12 months;the frequency for asthma attacked during the last 12 months;incidence of admitting to clinic (Integrated Chinese Medicine & Western Medicine Clinic) when asthma attack during the last 12 months;times of admitting to clinic;times of solving by persistent medicine;times of solving by own medicine when asthma attack during the last 12 months;and symptoms associated with Chinese medicine of waking by asthma symptoms, lack of strength, lassitude, rapid or difficult breathing were improved at the 1st course, the 2nd course and the 3rd course compared with baseline (All P < 0.05);2) The incidence of admitting to In-patient Hospital and solving by persistent prescription when asthma attacked;the frequency of Chinese Herbal Medicine used during Tianjiu Therapy;the status of asthma under controlled and no improved by self-evaluation were similarly improved at the 2nd course and the 3rd course (All P 3) Incidence of admitting to A & E for asthma attacked during the last 12 months, and other treatments except Western Medicine, Chinese Herbal Medicine, and Acupuncture & Moxibution during the last 12 months were improvement at the 3rd course (All P 4) Symptoms associated with Chinese medicine of spontaneous sweating and reduction of exercise were improved at the 1st course (P < 0.05);5) Symptom of diarrhea after intake of oil food was became a little bad at the 2nd course and the 3rd course (P < 0.05);6) The frequency of bronchodilator used when asthma attack was reduced in the 1st course and the 2nd course (All P < 0.05);7) Lung function of FEV1 and FEV1/FVC(×100) were a little improvement, but have no significant statistical difference (P > 0.05);8) The total score of ACT at the 1st course, the 2nd course, and the 3rd course did not improved significantly (All P > 0.05). Conclusion: After Tianjiu Therapy in Sanfu Days participants have achieved good efficiency, and as the course get longer, the efficiency of more symptoms associated with chronic asthma were improved. Suggest patients with chronic asthma continuous receive Tianjiu Therapy in Sanfu Days which will be a feasible treatment.
文摘In the present paper, the therapeutic effect of acupoint application of Chinese Materia Medica in the treatment of allergic asthma was observed. The results revealed that topical application of drug paste [mixture of powder of Mahuang (Herba Ephedrae), Xixin (Herba Asari), Baijiezi (Semen Sinapis Albae), etc.] at the acupuncture points could improve symptoms and signs of allergic asthma patients, with the total effective rate being 69.57% (16/23) for the short term effect, and 52.17%(12/23) for the long term effect. In medication (Aminophylline) group, of the 25 cases of allergic asthma, 16 (64.0%) were effective after 4 weeks of treatment, while 6 (24.0%) were still effective that was shown by 6 months’ follow up. The therapeutic effect of acupoint application group was significantly better than that of medication group in the long term effect. Results also showed that no obvious interrelation between the short term therapeutic effect and the duration or the severity of the disease. Results also display that acupoint application therapy is an effective, safe and handy method with fewer side effects for asthma.
文摘【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMed、Web of Science等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验,应用Stata14对数据进行网状Meta分析。【结果】最终纳入28项研究,包括7种中成药,分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示,在提高总有效率方面,优选概率排名曲线(surface under the cumulative ranking curve,SUCRA)的概率排序居前3位的依次为痰热清注射液联合吸入疗法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法;改善肺功能指标呼气峰值流速(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume at one second,FEV1)、FEV1与用力肺活量(forced vital capacity,FVC)的比值(FEV1/FVC)最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法;对不良反应发生率的SUCRA概率排序的分析结果显示,小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施,珠贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘的有效率及改善肺功能指标,且安全性较好。
